Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics (NASDAQ:NKTR) represented a move of 0.35 percent or $0.78 per share and closed its previous day trading session at $40.53. 3.13 Million Shares were traded in the last trading session with an Average Volume of 2.46 Million Shares. The stock currently has a Market Capitalization of 7 Billion.
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company’s wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
The stock traded between $ 33.50 and $111.36 over 1-Year time period showing its price to sales ratio of 5.6. Nektar Therapeutics (NASDAQ:NKTR) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-9.1 and 200-Day Simple Moving Average of $-38.78. Its Price to Free Cash Flow is 9.36 and Price to Book of 3.91.
Analyst’s recommended the stock as 1.8 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Nektar Therapeutics (NASDAQ:NKTR) reported its Actual EPS of $-0.56/share. The analysts offering Earnings Estimates for the company were believing that Nektar Therapeutics could bring EPS of $-0.63/share. The difference between Actual EPS and Estimated EPS was 0.07 Percent. Thus showing an Earnings Surprise of 11.1 Percent.
Akers Biosciences Inc (NASDAQ:AKER)
In the last trading session, Akers Biosciences Inc (NASDAQ:AKER) added its value by -3.97% closing at the price of $1.45. The stock currently has market capitalization of 19.78 Million, with average volume of 873.59 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Akers Biosciences Inc (NASDAQ:AKER) is showing beta of -1.56. This particular value of beta suggests that Akers Biosciences Inc (NASDAQ:AKER) has historically moved -156% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Akers Biosciences Inc (NASDAQ:AKER) is at $-3.09.
The stock currently has RSI of 35.51. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Akers Biosciences, Inc. develops, manufactures and supplies rapid, point-of-care screening and testing products. The Company’s products primarily includes BreathScan(R), BreathScan PRO(R), METRON(R), VIVO(TM), Heparin/PF4 Antibody Serum Panels(R) and Breath Ketone. Akers Biosciences, Inc. is based in Thorofare, United States.
Akers Biosciences Inc (NASDAQ:AKER) topped its 52-week high price of $7.84 on 03/26/18 and 52-Week Low Price of $0.96 on 12/22/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 8.08% and monthly volatility of 19.57% respectively.